Total Synthesis and Reassessment of the Phosphatase-Inhibitory Activity of the Antitumor Agent TMC-69-6H

Angewandte Chemie - International Edition

Volumn 42, Issue 43, 2003, Pages 5361-5364

  Fürstner, Alois ^a   Feyen, Fabian ^a   Prinz, Heino ^b   Waldmann, Herbert ^b  

^a MAX PLANCK INSTITUT FÜR KOHLENFORSCHUNG   (Germany)

^b MAX PLANCK INSTITUTE OF MOLECULAR PHYSIOLOGY   (Germany)

Author keywords

Heterocycles; Natural products; Palladium; Phosphatases; Structure activity relationships

Indexed keywords

CATALYSIS; CHEMICAL BONDS; SYNTHESIS (CHEMICAL); TUMORS;

ANTITUMOR AGENTS;

ENZYME INHIBITION;

ANTINEOPLASTIC AGENT; PHOSPHATASE; TMC 69 6H; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL PROCEDURES; DRUG ACTIVITY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ENANTIOSELECTIVITY; ENZYME INHIBITION; INHIBITION KINETICS; REPRODUCIBILITY; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ANTINEOPLASTIC AGENTS; CATALYSIS; CDC25 PHOSPHATASE; CELL CYCLE PROTEINS; HYDROGENATION; INHIBITORY CONCENTRATION 50; ISOENZYMES; NITROPHENOLS; ORGANOPHOSPHORUS COMPOUNDS; OXIDATION-REDUCTION; PALLADIUM; PYRANS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0345306825     PISSN: 14337851     EISSN: None     Source Type: Journal    
DOI: 10.1002/anie.200352268     Document Type: Article

References (61)

1. For reviews, see: a) K. Galaktinov, A. K. Lee, J. Eckstein, G. Draetta, J. Meckler, M. Loda, D. Beach, Science 1995, 269, 1575-1577;
2. b) G. Draetta, J. Eckstein, Biochim. Biophys. Acta 1997, 1332, M53-M63;
3. c) I. Nilsson, I. Hoffmann, Prog. Cell Cycle Res. 2000, 4, 107-114;
4. d) Z.-Y. Zhang, Curr. Opin. Chem. Biol. 2001, 5, 416-423.
5. Selected articles: a) M. G. Cangi, B. Cukor, P. Soung, S. Signoretti, G. Moreira, M. Ranashinge, B. Cady, M. Pagano, M. Loda, J. Clin. Invest. 2000, 106, 753-761;
6. b) D. Dixon, T. Moyana, M. J. King, Exp. Cell Res. 1998, 240, 236-243;
7. c) D. Gasparotto, R. Maestro, S. Piccinin, T. Vukosavljigevic, L. Barman, S. Sulfaro, M. Boiocchi, Cancer Res. 1997, 57, 2366-2368;
8. d) W. Wu, Y. H. Fan, B. L. Kemp, G. Walsh, L. Mao, Cancer Res. 1998, 58, 4082-4085.
9. a) For comprehensive literature coverage, see: M. A. Lyon, A. P. Ducruet, P. Wipf, J. S. Lazo, Nat. Rev. Drug Discovery 2002, 1, 961-976;
10. b) for a representative study, see: D. Brohm, N. Philippe, S. Metzger, A. Bhargava, O. Müller, F. Lieb, H. Waldmann, J. Am. Chem. Soc. 2002, 124, 13171-13178.
11. a) N. Hirano, J. Kohno, S. Tsunoda, M. Nishio, N. Kishi, T. Okuda, K. Kawano, S. Komatsubara, N. Nakanishi, J. Antibiot. 2001, 54, 421-427;
12. b) J. Kohno, N. Hirano, K. Sugawara, M. Nishio, T. Hashiyama, N. Nakanishi, S. Komatsubara, Tetrahedron 2001, 57, 1731-1735;
13. c) see also: K. Sugawara, J. Kohno, N. Nakanishi, T. Hashiyama, Tennen Yuki Kagobutsu Toronkai Koen Yoshishu 2000, 42, 661-666 [Chem. Abstr. 2001, 134, 340370].
14. c) see also: K. Sugawara, J. Kohno, N. Nakanishi, T. Hashiyama, Tennen Yuki Kagobutsu Toronkai Koen Yoshishu 2000, 42, 661-666 [Chem. Abstr. 2001, 134, 340370].
15. H. M. R. Hoffmann, H. Krumwiede, B. Mucha, H. Oehlerking, G. W. Prahst, Tetrahedron 1993, 49, 8999-9018.
16. a) G. Grynkiewicz, A. Zamojski, Z. Naturforsch. B 1980, 35, 1024-1027;
17. b) M.T Reetz, H. Müller-Starke, Liebigs Ann. Chem. 1983, 1726-1738.
18. H. van der Deen, A. van Oeveren, R. M. Kellogg, B. L. Feringa, Tetrahedron Lett. 1999, 40, 1755-1758.
19. a) B. B. Snider, Q. Lu, J. Org. Chem. 1996, 61, 2839-2844;
20. b) J. Buck, J. P. Madeley, G. Pattenden, J. Chem. Soc. Perkin Trans. 1 1992, 67-77.
21. M. Moreno-Manas, R. Pleixats, M. Villarroya, Tetrahedron 1993, 49, 1457-1464.
22. a) B. M. Trost, D. L. van Vranken, Chem. Rev. 1996, 96, 395-422;
23. b) B. M. Trost, C. B. Lee, J. Am. Chem. Soc. 2001, 123, 3671-3686.
24. M. van den Heuvel, A. D. Cuiper, H. van der Deen, R. M. Kellogg, B. L. Feringa, Tetrahedron Lett. 1997, 38, 1655-1658.
25. a) M. J. Robins, C. Kaneko, M. Kaneko, Can. J. Chem. 1981, 59, 3356-3359;
26. b) B. B. Snider, Q. Lu, Tetrahedron Lett. 1994, 35, 531-534.
27. a) P. R. Blakemore, W. J. Cole, P. Kocienski, A. Morley, Synlett 1998, 26-28;
28. b) review: P. R. Blakemore, J. Chem. Soc. Perkin Trans. 1 2002, 2563-2585;
29. for a recent application, see: A. Fürstner, J. Mlynarski, M. Albert, J. Am. Chem. Soc. 2002, 124, 10274-10275.
30. For the regioselective ozonolysis of citronellene and related olefinations of the resulting aldehyde, see: a) A. M. G. Barrett, R. Carr, S. V. Attwood, G. Richardson, N. D. A. Walshe, J. Org. Chem. 1986, 51, 4840-4856;
31. b) M. G. Banwell, C. T. Bu, G. W. Simpson, J. Chem. Soc. Perkin Trans. 1 1998, 791-800.
32. 10,H11eq = 2.6 Hz.
33. a) S. A. Matlin, P. G. Sammes, R. M. Upton, J. Chem. Soc. Perkin Trans. 1 1979, 2481-2487; b) J. H. Rigby, M. Qabar, J. Org. Chem. 1989, 54, 5852-5853;
34. b) J. H. Rigby, M. Qabar, J. Org. Chem. 1989, 54, 5852-5853.
35. a) E. Vedejs, S. Larsen, Org. Synth. 1986, 64, 127-137;
36. H. Mimoun, I. S. de Roch, L. Sajus, Bull. Soc. Chim. Fr. 1969, 1481-1492.
37. 20 = + 88.6 (c = 0.50, MeOH).
38. a) Z.-Y. Zhang, Curr. Opin. Chem. Biol. 2001, 5, 416-423;
39. b) T. O. Johnson, J. Ermolieff, M. R. Jirousek, Nat. Rev. Drug Discovery 2002, 1, 696-709.
40. a) J. L. Todd, K. G. Tanner, J. M. Denu, J. Biol. Chem. 1999, 274, 13271-13280;
41. b) T. Usui, S. Kojima, S. Kidokoro, K. Ueda, U. Osada, M. Sodeoka, Chem. Biol. 2001, 8, 1209-1220.
42. a) J. B. Aggen, A. C. Nairn, R. Chamberlin, Chem. Biol. 2000, 7, R13-R23;
43. b) A. McCluskey, J. A. Sakoff. Mini-Rev. Med. Chem. 2001, 1, 43-55.
44. a) T. Hamaguchi, A. Masuda, T. Morino, H. Osada, Chem. Biol. 1997, 4, 279-286;
45. b) A. Takai, G. Mieskes, Biochem. J. 1991, 275, 233-239;
46. c) Vertebrate Phototransduction and the Visual Cycle Pt. A: X. Huang, M. R. Swingle, R. E. Honkanen, Methods Enzymol. 2000, 315, 579-593.
47. While several other bioactive natural products that contain an N-hydroxy-2-pyridone motif are known in the literature, it appears that none have been checked for phosphatase inhibition; see: a) militarinone A: K. Schmidt, W. Günther, S. Stoyanova, B. Schubert, Z. Li, M. Hamburger, Org. Lett. 2002, 4, 197-199;
48. b) militarinone D: K. Schmidt, U. Riese, Z. Li, M. Hamburger, J. Nat. Prod. 2003, 66, 378-383;
49. c) tenellin: S. H. El Basyouni, D. Brewer, L. C. Vining, Can. J. Bot. 1968, 46, 441-448;
50. d) bassianin: C.-K. Wat. A. G. McInnes, D. G. Smith, J. L. C. Wright, L. C. Vining, Can. J. Chem. 1977, 55, 4090-4098;
51. e) fischerin: H. Fujimoto, M. Ikeda, K. Yamamoto, M. Yamazaki, J. Nat. Prod. 1993, 56, 1268-1275;
52. f) pyridomacrolidin: S. Takahashi, N. Kakinuma, K. Uchida, R. Hashimoto, T. Yanagisawa, A. Nakagawa, J. Antibiot. 1998, 51, 596-598;
53. g) leporin A: M. R. Tepaske, J. B. Gloer, D. T. Wicklow, P. F. Dowd, Tetrahedron Lett. 1991, 32, 5687-5690;
54. h) fusaricide: K. D. McBrien, Q. Gao, S. Huang, S. E. Klohr, R. R. Wang, D. M. Pirnik, K. M. Neddermann, I. Bursuker, K. F. Kadow, J. E. Leet, J. Nat. Prod. 1996, 59, 1151-1153;
55. i) pyridoxatin: Y. Teshima, K. Shin-ya, A. Shimazu, K. Furihata, H. S. Chul, K. Furihata, Y. Hayakawa, K. Nagai, H. Seto, J. Antibiot. 1991, 44, 685-687;
56. j) BN-227: J. Itoh, S. Amano, Y. Ogawa, Y. Kodama, N. Ezaki, Y. Yamada, J. Antibiot. 1980, 33, 377-382.
57. The same pertains to structurally related 2-pyridone alkaloids that are not oxidized at the nitrogen center; see: k) funiculosin: K. Ando, I. Matsuura, Y. Nawata, H. Endo, H. Sasaki, T. Okytomi, T. Saehi, G. Tamura, J. Antibiot. 1978, 31, 533-538;
58. l) sambutoxin: J.-C. Kim, Y.-W. Lee, H. Tamura, T. Yoshizawa, Tetrahedron Lett. 1995, 36, 1047-1050;
59. m) oxysporidinone: J. Breinholt, S. Ludvigsen, B. R. Rassing, C. N. Rosendahl, S. E. Nielsen, C. E. Olsen, J. Nat. Prod. 1997, 60, 33-35;
60. n) harzianopyridone: J. M. Dickinson, J. R. Hanson, P. B. Hitchcock, N. Claydon, J. Chem. Soc. Perkin Trans. 1 1989, 1885-1887.
61. For a structurally different synthetic 2-pyridone derivative that bears an N-methylphosphonate moiety, which exhibits phosphatase-inhibiting properties, see: J.-M. Fu, A. L. Castelhano, Bioorg. Med. Chem. Lett. 1998, 8, 2813-2816.